The study includes an initial safety run-in phase followed by an expansion phase, aiming to evaluate 6-month progression-free survival among other objectives. Compass is also conducting a second ...

Shares of oncology-focused biopharma Compass Therapeutics (NASDAQ ... including and overall survival (OS) has yet to meet the company's initial targets, and it expects to post these findings ...

but only one survivalist can claim it in time. In the final challenge, the families must guide their survivalists to crates filled with supplies using only a compass in the all-new 'Mystery Box ...